Julie Cooke Sells 12,632 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 12,632 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the transaction, the insider now owns 18,202 shares of the company’s stock, valued at approximately $2,789,638.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Julie Cooke also recently made the following trade(s):

• On Tuesday, July 16th, Julie Cooke sold 900 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $150.04, for a total transaction of $135,036.00.
• On Monday, July 1st, Julie Cooke sold 10,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $140.19, for a total transaction of $1,401,900.00.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded down $5.44 during trading hours on Monday, hitting $147.70. 909,565 shares of the stock were exchanged, compared to its average volume of 826,283. The company has a market cap of $14.86 billion, a PE ratio of 41.04 and a beta of 0.37. The company’s fifty day simple moving average is $139.82 and its two-hundred day simple moving average is $138.46. Neurocrine Biosciences, Inc. has a 1-year low of $100.52 and a 1-year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.52). The company had revenue of $590.20 million during the quarter, compared to the consensus estimate of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. Neurocrine Biosciences’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.95 EPS. As a group, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NBIX has been the subject of a number of analyst reports. HC Wainwright raised their price target on shares of Neurocrine Biosciences from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday. Wells Fargo & Company upgraded shares of Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $140.00 to $170.00 in a research note on Wednesday, April 24th. BMO Capital Markets lifted their target price on shares of Neurocrine Biosciences from $129.00 to $138.00 and gave the company a “market perform” rating in a research note on Thursday, May 2nd. Oppenheimer lifted their target price on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research note on Friday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Neurocrine Biosciences from $169.00 to $173.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $158.36.

Hedge Funds Weigh In On Neurocrine Biosciences

Large investors have recently modified their holdings of the business. Mather Group LLC. acquired a new stake in Neurocrine Biosciences in the first quarter worth $26,000. RFP Financial Group LLC grew its holdings in shares of Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after buying an additional 149 shares during the last quarter. Lindbrook Capital LLC grew its holdings in shares of Neurocrine Biosciences by 85.0% during the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after buying an additional 96 shares during the last quarter. Innealta Capital LLC acquired a new position in shares of Neurocrine Biosciences during the second quarter valued at about $30,000. Finally, EdgeRock Capital LLC acquired a new position in shares of Neurocrine Biosciences during the fourth quarter valued at about $31,000. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.